Holdings

Symbol Grade Price % Change Allocation
IFF B 0.28 4.95
RTX D -0.37 4.84
SCHW D -1.25 4.38
MO A 0.33 4.28
CPB B 0.24 3.98
PFE C 1.26 3.93
MAS D -0.12 3.90
BIIB C 0.46 3.88
MDT D 0.57 3.86
USB D -1.19 3.81

Recent News for SHL Telemedicine Ltd VanEck Morningstar Wide Moat Value ETF & its Holdings

Date Stock Title
Jul 5 CPB How Is The Market Feeling About Campbell Soup?
Jul 5 MO Altria Pays You Handsomely To Wait For Future Growth
Jul 5 SCHW Charles Schwab Insiders Sold US$62m Of Shares Suggesting Hesitancy
Jul 5 PFE Executive reshuffles: NIO, Pfizer and Spirit Airlines in focus
Jul 5 PFE Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code
Jul 5 PFE Pfizer names former State Street CEO Taraporevala to board
Jul 5 MO Altria: 3 Things You Need To Know About This 9% Yielding Dividend Aristocrat
Jul 5 MO Altria Investors Just Got Some Bullish News
Jul 5 PFE 3 Dividend Stocks That Are Screaming Buys in July
Jul 5 MO Best Stock to Buy Right Now: Altria Group vs. British American Tobacco
Jul 4 MAS Masco Lost 16% in 3 Months: Should You Buy MAS Stock on the Dip?
Jul 4 MO 3 Reasons to Buy Altria Stock Like There's No Tomorrow
Jul 4 MO Can These 2 Ultra-High-Yield Dividend Stocks Outperform the S&P 500 in 2024?
Jul 4 PFE Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 68% of the company
Jul 3 MO Altria Group, Inc. (MO): Is It the Best Dividend Aristocrat To Buy Now?
Jul 3 MO A Bull Market Is Here: 2 Brilliant Stocks Down 41% and 51% to Buy Right Now
Jul 3 BIIB Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More
Jul 3 BIIB Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
Jul 3 PFE GSK Will Pay Up to $1.5 Billion for CureVac’s mRNA Vaccines
Jul 3 PFE Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
The fund invests at least 80% of its total assets in securities that comprise the fund"s benchmark index. The index is comprised of equity securities of companies that Morningstar, Inc. determines have sustainable competitive advantages based on a proprietary methodology that considers quantitative and qualitative factors and are attractively priced and weighted according to a modified equal weighting scheme that tilts exposure in favor of pure value companies. It is non-diversified.
Morningstar
Back to the Main MVAL Page...